{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.13","upperLimit":"0.40","value":"0.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"Major erythroid response is defined as transfusion-independence for ≥ 8 consecutive weeks for patients who were red blood cell transfusion-dependent at baseline AND a ≥ 1 g/dL hemoglobin rise compared to mean pre-transfusion baseline value; or a \\> 2 g/dL rise in hemoglobin without transfusion for non-transfusion dependent patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.","id":"OG000","title":"Arm B (Lenalidomide + Epoetin Alfa; Crossover)"}],"paramType":"NUMBER","populationDescription":"Evaluable patients who fail to experience a MER with lenalidomide monotherapy and receive salvage combination therapy (crossover from arm A to arm B)","reportingStatus":"POSTED","timeFrame":"Assessed after completion of 16 weeks of treatment","title":"Proportion of Patients With Major Erythroid Response (MER) to Salvage Combination Therapy","type":"SECONDARY","unitOfMeasure":"proportion of participants"}